Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549196 · ClinicalTrials.gov registry record · Phase 2
A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
A Phase 2 study of Dementia of Alzheimer's Type, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT02549196 is a Phase 2 study of Dementia of Alzheimer's Type that has completed, run by Chase Pharmaceuticals Corporation, an affiliate of Allergan. The registered enrollment target is 28 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT02549196, a Phase 2 study of Dementia of Alzheimer's Type, has completed, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
Conditions Studied
Interventions
- DRUG Donepezil
- DRUG Solifenacin
Study Locations (4)
Florida
- Quantum Laboratories - Deerfield Beach
- Miami Jewish Health Systems - Miami
- Premiere Research Institute - West Palm Beach
North Carolina
- PMG Research - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-10-07 |
| Est. Completion | 2017-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02549196
The ClinicalTrials.gov registry entry for NCT02549196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dementia of Alzheimer's Type appearing as the primary indexed condition, and to 2 interventions - of which Donepezil is the first listed.
NCT02549196 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02549196 about?
NCT02549196 is a clinical study titled "A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type". This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
What is the current status of trial NCT02549196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2015-10-07. Estimated completion is 2017-09-28.
What conditions does trial NCT02549196 study?
This clinical trial studies the following conditions: Dementia of Alzheimer's Type.
What interventions are being tested in trial NCT02549196?
The interventions under investigation include: Donepezil (DRUG), Solifenacin (DRUG).
Who is sponsoring clinical trial NCT02549196?
This trial is sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02549196 being conducted?
This trial has 4 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.